Insider Selling: Adaptive Biotechnologies (NASDAQ:ADPT) COO Sells 19,060 Shares of Stock

Posted by Brian Himes on Apr 24th, 2026

Adaptive Biotechnologies Corporation (NASDAQ:ADPT – Get Free Report) COO Julie Rubinstein sold 19,060 shares of the business’s stock in a transaction that occurred on Wednesday, April 22nd. The shares were sold at an average price of $14.13, for a total transaction of $269,317.80. Following the completion of the sale, the chief operating officer directly owned 390,808 shares in the company, valued at approximately $5,522,117.04. This trade represents a 4.65% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Julie Rubinstein also recently made the following trade(s):

On Friday, April 24th, Julie Rubinstein sold 19,060 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $14.02, for a total transaction of $267,221.20.
On Tuesday, April 21st, Julie Rubinstein sold 30,941 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $14.66, for a total transaction of $453,595.06.
On Monday, April 20th, Julie Rubinstein sold 19,060 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $14.55, for a total transaction of $277,323.00.
On Thursday, April 16th, Julie Rubinstein sold 19,060 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $14.18, for a total transaction of $270,270.80.
On Monday, April 13th, Julie Rubinstein sold 19,060 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $13.15, for a total transaction of $250,639.00.
On Friday, April 10th, Julie Rubinstein sold 19,060 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $12.77, for a total transaction of $243,396.20.
On Tuesday, April 7th, Julie Rubinstein sold 19,060 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $13.56, for a total transaction of $258,453.60.
On Wednesday, April 8th, Julie Rubinstein sold 30,941 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $14.83, for a total transaction of $458,855.03.
On Wednesday, April 1st, Julie Rubinstein sold 19,060 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $14.45, for a total transaction of $275,417.00.
On Monday, March 23rd, Julie Rubinstein sold 19,060 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $13.83, for a total transaction of $263,599.80.

Adaptive Biotechnologies Stock Up 2.3%

NASDAQ:ADPT traded up $0.32 during mid-day trading on Friday, hitting $14.14. 876,143 shares of the stock traded hands, compared to its average volume of 1,978,338. The business’s 50-day moving average price is $14.50 and its 200 day moving average price is $15.97. The company has a market cap of $2.18 billion, a PE ratio of -35.35 and a beta of 2.29. Adaptive Biotechnologies Corporation has a 12-month low of $7.16 and a 12-month high of $20.76.

Adaptive Biotechnologies (NASDAQ:ADPT – Get Free Report) last issued its quarterly earnings data on Thursday, February 5th. The company reported ($0.09) EPS for the quarter, beating the consensus estimate of ($0.19) by $0.10. The company had revenue of $71.68 million during the quarter, compared to analysts’ expectations of $59.38 million. Adaptive Biotechnologies had a negative net margin of 21.48% and a negative return on equity of 46.68%. Adaptive Biotechnologies’s revenue for the quarter was up 51.0% on a year-over-year basis. During the same quarter in the previous year, the company earned ($0.23) earnings per share. Analysts anticipate that Adaptive Biotechnologies Corporation will post -0.5 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms have commented on ADPT. Weiss Ratings reissued a “sell (d-)” rating on shares of Adaptive Biotechnologies in a research note on Monday. BTIG Research boosted their price target on shares of Adaptive Biotechnologies from $21.00 to $22.00 and gave the stock a “buy” rating in a research note on Friday, February 6th. TD Cowen reissued a “buy” rating on shares of Adaptive Biotechnologies in a research note on Friday, February 6th. JPMorgan Chase & Co. boosted their price target on shares of Adaptive Biotechnologies from $20.00 to $21.00 and gave the stock an “overweight” rating in a research note on Friday, February 6th. Finally, Wall Street Zen cut shares of Adaptive Biotechnologies from a “buy” rating to a “hold” rating in a research note on Saturday, March 7th. Seven analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Adaptive Biotechnologies currently has a consensus rating of “Moderate Buy” and an average target price of $18.25.

Check Out Our Latest Research Report on Adaptive Biotechnologies

Hedge Funds Weigh In On Adaptive Biotechnologies

A number of hedge funds and other institutional investors have recently bought and sold shares of ADPT. Westfield Capital Management Co. LP purchased a new position in Adaptive Biotechnologies in the 4th quarter worth approximately $65,942,000. Price T Rowe Associates Inc. MD grew its stake in Adaptive Biotechnologies by 303.4% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 4,387,361 shares of the company’s stock worth $71,252,000 after buying an additional 3,299,635 shares in the last quarter. Ameriprise Financial Inc. lifted its holdings in shares of Adaptive Biotechnologies by 84.3% in the 3rd quarter. Ameriprise Financial Inc. now owns 5,971,706 shares of the company’s stock worth $89,337,000 after acquiring an additional 2,731,648 shares during the last quarter. Invesco Ltd. lifted its holdings in shares of Adaptive Biotechnologies by 248.8% in the 4th quarter. Invesco Ltd. now owns 3,107,653 shares of the company’s stock worth $50,468,000 after acquiring an additional 2,216,595 shares during the last quarter. Finally, Arrowstreet Capital Limited Partnership lifted its holdings in shares of Adaptive Biotechnologies by 544.0% in the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 2,441,402 shares of the company’s stock worth $36,523,000 after acquiring an additional 2,062,282 shares during the last quarter. Hedge funds and other institutional investors own 99.17% of the company’s stock.

Adaptive Biotechnologies Company Profile

(Get Free Report)

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.